Prions – Definition, Structure, Characteristics, Replication and Diseases

Learn about prions, their structure, characteristics, replication mechanism, transmission, and diseases affecting humans and animals.

Summarise with AI:

Prions are studied in microbiology and molecular biology along with other infectious agents. They are associated with rare neurodegenerative diseases affecting humans and other mammals.

Creutzfeldt-Jakob disease (CJD) is one of the prion diseases found in humans. These diseases affect the nervous system and are fatal once symptoms develop.

What are Prions?

A prion is an infectious, abnormally folded protein that can cause susceptible forms of the same protein to change their normal shape. The term prion means “proteinaceous infectious particle”. These infectious agents are made up of protein and do not contain a DNA or RNA genome. Prions are neither viruses nor living microorganisms.

The protein associated with prions is called prion protein (PrP). It is normally present in human cells in the form of cellular prion protein (PrPᶜ). The abnormal disease-associated form is known as PrPˢᶜ.

Normal PrPᶜ is also found in healthy people. Its presence does not mean that a person has infectious prions or prion disease.

Structure of Prion Proteins

The structure of prions is based on the host prion protein (PrP). The human PRNP gene encodes a precursor protein of 253 amino acids. After processing, the mature prion protein contains about 208–209 amino acids and is attached to the cell membrane by a glycosylphosphatidylinositol (GPI) anchor.

A prion diagram generally shows the flexible N-terminal region, the globular C-terminal region, glycosylation sites and the GPI anchor. The same prion protein can occur in the normal cellular form (PrPᶜ) and in disease-associated conformations (PrPˢᶜ).

Comparison of membrane-anchored normal prion protein with three alpha helices and infectious prion protein forming beta-sheet-rich amyloid fibrils.
Normal cellular prion protein (PrPᶜ) has a predominantly α-helical C-terminal domain, while disease-associated PrPˢᶜ adopts abnormal β-sheet-rich conformations that can form infectious fibrils.

Normal Cellular Prion Protein (PrPᶜ)

The structure of normal cellular prion protein is given below:

  • PrPᶜ is a glycoprotein present mainly on the outer surface of the cell membrane. It is attached to the membrane by a GPI anchor.
  • The N-terminal part of PrPᶜ is flexible and largely disordered. The C-terminal part forms a globular domain.
  • The globular domain contains three alpha helices and two short beta-strands. A disulfide bond is present between cysteine residues 179 and 214 in human PrP.
  • The N-terminal region also contains an octapeptide repeat region that can bind copper ions.
  • PrPᶜ has been associated with cell signalling, copper homeostasis and several neuronal processes. Its normal physiological function is still not completely established.
  • The PRNP gene is a normal human gene. The presence of this gene does not mean that a person has prion disease.
  • Pathogenic variants of PRNP can cause genetic prion diseases. Sporadic and acquired prion diseases can occur without an inherited pathogenic PRNP variant.

Infectious Prion Protein (PrPˢᶜ)

The structural characteristics of infectious PrPˢᶜ are given below:

  • PrPˢᶜ is an abnormally folded form of the host prion protein. It is not a separate protein encoded by a pathogen genome.
  • PrPˢᶜ contains much more beta-sheet structure than PrPᶜ, whereas PrPᶜ is mainly alpha-helical.
  • PrPˢᶜ molecules associate with one another and form aggregates. Infectious prions can form amyloid fibrils.
  • PrPᶜ is soluble in mild detergents, while aggregated PrPˢᶜ is generally detergent-insoluble.
  • PrPᶜ is readily digested by proteases. PrPˢᶜ usually shows partial resistance to proteinase K, although protease-sensitive disease-associated PrP forms are also present.
  • Different infectious prions do not necessarily have exactly the same folded structure. Different prion strains are associated with different PrPˢᶜ conformations and fibril structures.
  • The change from PrPᶜ to PrPˢᶜ mainly involves a change in protein conformation. The abnormal form can then promote the conversion of other PrP molecules into a similar misfolded form.

Differences Between PrPᶜ and PrPˢᶜ

The differences between PrPᶜ and PrPˢᶜ are given below:

CharacteristicsPrPᶜ (Normal Prion Protein)PrPˢᶜ (Infectious Prion Protein)
1. Protein originIt is the normal cellular protein encoded by the PRNP gene.It is the abnormally folded form of the same host protein. Both have the same amino acid sequence.
2. Predominant conformationIt contains mainly alpha-helices (α-helices) with two short beta-strands.It contains more beta-sheets (β-sheets) and fewer alpha-helices.
3. AggregationIt is normally present as individual protein molecules.These proteins join together and form aggregates, including amyloid fibrils.
4. SolubilityIt is soluble in mild detergents.It is generally insoluble in mild detergents.
5. Protease susceptibilityIt is easily digested by proteolytic enzymes such as proteinase K.It is partially resistant to proteinase K. Some infectious forms are also sensitive to protease digestion.
6. Involvement in diseaseIt is present in healthy cells and does not indicate prion disease.It is the disease-associated form involved in prion infections.

Characteristics of Prions

The general characteristics of prions are given below:

  • Prions are proteinaceous infectious agents. They do not contain DNA or RNA.
  • These are acellular agents without cytoplasm, ribosomes and other cell organelles.
  • Prions are not living organisms. They have no independent metabolism and cannot produce their own energy.
  • They cannot propagate independently and require the normal cellular prion protein (PrPᶜ) of the host.
  • The infectious prion protein has an abnormal and relatively stable conformation.
  • The abnormal proteins join together and form aggregates. Some of them form amyloid fibrils.
  • Many infectious prion forms are resistant to proteolytic enzymes such as proteinase K. Protease-sensitive forms are also present.
  • Prions are resistant to conventional heat and several chemical treatments. Boiling and routine disinfection may not completely inactivate them.
  • Different prion strains may have the same amino acid sequence but different protein conformations.
  • These strains can differ in their incubation period, tissue distribution and other biological properties.
  • Prion strains are conformational forms of the infectious protein and are different from the diseases caused by prions.

Origin of Pathogenic Prions

Three pathways showing sporadic PrP misfolding, inherited PRNP variants, and exposure to infectious prion material leading to pathogenic prion seeds.
Pathogenic prion conformations may arise through sporadic events, inherited PRNP variants, or acquired infectious exposure. These origins differ from the later amplification of prions within host tissues.

Pathogenic prions can arise in the following ways:

  • Sporadic prion disease occurs without a known external source of infection or an inherited pathogenic PRNP variant. A normal prion protein (PrP) is believed to undergo an abnormal conformational change and form the disease-associated protein.
  • In genetic prion disease, a pathogenic variant of the PRNP gene is inherited from a parent. The altered prion protein has a greater tendency to form abnormal conformations.
  • The PRNP variant is inherited, not necessarily an infectious prion protein itself. A person carrying the variant may remain without symptoms for many years, and the disease is not usually present at birth.
  • Acquired prion disease starts when infectious prion material enters the body from an external source. This can occur through contaminated food, infected tissues or certain medical exposures.
  • Once a pathogenic prion conformation is present, it can change normal PrP into the abnormal form. More abnormal PrP is then produced within the affected tissues.
  • The first appearance of a pathogenic conformation is different from its later amplification. Sporadic misfolding, a PRNP variant or an external prion can provide the initial abnormal form.
  • Transmission between two hosts is also different from prion amplification within one host. Sporadic and genetic prion diseases can arise without transmission from another infected individual.

Replication of Prions

Prions replicate by converting the normal cellular prion protein (PrPᶜ) into the abnormal PrPˢᶜ form. It is a propagation of protein conformation and does not involve the replication of DNA or RNA. No cell division takes place during this process.

Template-Directed Conversion of Prion Proteins

  • The normal PrPᶜ is produced by the host cells and acts as the substrate for prion replication.
  • PrPˢᶜ interacts with a susceptible PrPᶜ molecule. The abnormal protein acts as a template for the structural change of PrPᶜ.
  • The PrPᶜ changes its normal conformation and forms a disease-associated PrP molecule with a conformation compatible with the prion seed.
  • No change in the DNA sequence is required for this conversion. The newly converted protein differs mainly in its conformation from the normal cellular protein.
  • The newly formed PrPˢᶜ can take part in the conversion of other PrPᶜ molecules. In this way, the abnormal conformation is passed from one protein molecule to another.
  • The infectious information in prions is therefore present in the protein conformation rather than in a DNA or RNA genome. Different stable conformations can also help in the propagation of different prion strains.
  • Prion replication is different from DNA replication, where a DNA strand is copied, and RNA replication, where new RNA molecules are produced from an RNA template. It is also different from cell division because no new cell is formed.
  • The host cell still produces PrPᶜ by normal gene expression. Prion propagation uses these cellular PrP molecules for further conformational conversion.

Aggregation and Propagation of Prions

  • The converted PrP molecules join the existing prion seed and the aggregate increases in size.
  • More PrPᶜ molecules are recruited to the growing aggregate and are converted into the abnormal conformation. This leads to the elongation of the prion aggregate.
  • The growing aggregates may form larger fibrils. These fibrils provide sites where additional PrP molecules can be added.
  • Large prion aggregates can break into smaller fragments. Each fragment can act as another seed for the conversion of PrPᶜ.
  • Fragmentation increases the number of propagation sites without producing a new nucleic acid genome. Secondary nucleation or seeding has also been proposed as another source of new seeds, although its importance can vary with the prion system.
  • These new seeds recruit more cellular PrP and the conversion continues again. Repeated conversion, aggregate growth and formation of new seeds increase the amount of disease-associated PrP in susceptible tissues.
  • Prion seeds can also move from one cell to another and start the same conversion in another susceptible cell. This allows the abnormal protein conformation to spread through tissues.
  • Propagation inside an infected host is different from transmission between two hosts. Transmission occurs when infectious prion material enters another host, while molecular propagation takes place after the prion reaches susceptible cells and begins converting their PrPᶜ.
Sequential prion replication mechanism showing normal PrP conversion at an infectious seed, amyloid fibril elongation, fragmentation and formation of new seeds.
Prion propagation occurs when infectious PrP conformations recruit normal PrPᶜ molecules, promoting conformational conversion and aggregate growth. Fragmentation can generate additional seeds capable of continuing the process.

Pathogenesis of Prion Diseases

The pathogenesis of prion diseases is given below:

  1. PrPˢᶜ continues to form from normal PrPᶜ and accumulates in the nervous tissue as the disease progresses.
  2. These abnormal proteins join together and form different protein aggregates. They may be present as small assemblies, fibrils or amyloid deposits.
  3. The amount and distribution of PrPˢᶜ can differ in different prion diseases and prion strains.
  4. Neuronal functions are affected during the disease. Changes in the synapses may occur before extensive loss of neurons.
  5. The affected neurons gradually degenerate and die.
  6. Neuronal loss occurs in different regions of the brain. The regions affected can vary with the type of prion disease.
  7. Astrocytes and microglia become activated in the affected brain tissue. This reaction is known as reactive gliosis.
  8. Vacuoles are formed in the neuropil and may also be present inside neurons. These vacuoles give the affected tissue a sponge-like appearance.
  9. This characteristic change is called spongiform vacuolation.
  10. Prion diseases are also called transmissible spongiform encephalopathies (TSEs). The term transmissible refers to the infectious nature of the prion agent, spongiform refers to the sponge-like changes in the brain, and encephalopathy refers to disease of the brain.
  11. The altered conformation of PrPˢᶜ helps in the continued conversion of normal PrPᶜ. More abnormal protein is formed and the neurological damage progresses with the disease.
  12. The amount of PrPˢᶜ deposited in the brain does not always correspond directly with the amount of neuronal loss. Different prion protein assemblies may have different effects on neurons.
  13. The exact mechanism by which prions damage and kill neurons is still not completely understood. Changes in synaptic function, protein processing, cellular stress and glial responses may be involved. A single mechanism has not been established for all prion diseases.
Nervous tissue schematic showing prion protein aggregates, disrupted synapses, spongiform vacuoles, reactive astrocytes, activated microglia and neuronal degeneration.
Prion diseases involve progressive neurological damage associated with abnormal PrP accumulation, synaptic dysfunction, neuronal loss, reactive gliosis and spongiform changes in brain tissue.

Prion Diseases in Humans and Animals

Prion diseases are progressive neurodegenerative diseases found in humans and several animals. The classification of prions in relation to disease refers to the diseases caused by prions and is different from the molecular prion strains.

Human Prion Diseases

The important human prion diseases are given below:

  1. Creutzfeldt-Jakob disease (CJD)– It is the most common human prion disease. It progresses rapidly and causes dementia, myoclonus, ataxia and other neurological abnormalities. CJD occurs in sporadic, genetic and iatrogenic forms.
  2. Variant Creutzfeldt-Jakob disease (vCJD)– It is associated with exposure to bovine spongiform encephalopathy (BSE) prions. It generally affects younger people and may begin with psychiatric and sensory symptoms followed by progressive neurological problems.
  3. Kuru– It is an acquired human prion disease that occurred mainly among the Fore people of Papua New Guinea. Tremor, unsteady gait and difficulty in speaking are common characteristics of the disease.
  4. Gerstmann-Sträussler-Scheinker syndrome (GSS)– It is a rare inherited prion disease. Loss of coordination and difficulty in walking develop gradually. Dementia may occur during the later stages.
  5. Fatal familial insomnia (FFI)– It is an inherited prion disease associated with pathogenic variants of the PRNP gene. Progressive loss of sleep is the main characteristic along with weight loss, autonomic disturbances and other neurological symptoms.
  6. Classification of human prion diseases– Human prion diseases can be sporadic, genetic or acquired depending upon their origin. This classification is different from prion strains, which refer to different conformational forms of the prion protein.

Animal Prion Diseases

The important animal prion diseases are given below:

  1. Bovine spongiform encephalopathy (BSE)– It is a prion disease of cattle and is commonly called “mad cow disease.” The affected animals develop abnormal behaviour, loss of coordination, difficulty in rising and weight loss.
  2. Scrapie– It occurs mainly in sheep and goats. The affected animals may show tremors, ataxia, abnormal gait, weight loss and repeated rubbing or scratching of the body.
  3. Chronic wasting disease (CWD)– It affects deer, elk, moose, reindeer and other cervids. Weight loss, stumbling, poor coordination, drooling and listlessness may occur in affected animals.
  4. CWD and humans– CWD has not been demonstrated to infect humans. Its possible zoonotic risk is still being investigated.
  5. Transmissible mink encephalopathy (TME)– It is a prion disease of mink and produces progressive neurological abnormalities.
  6. Feline spongiform encephalopathy (FSE)– It is a prion disease found in domestic and captive cats. The disease affects the nervous system and produces progressive neurological signs.

Different Methods of Transmission of Prions

The different methods by which prions are transmitted are given below:

Three prion transmission pathways showing BSE-contaminated food associated with human variant CJD, historical medical transmission of CJD, and CWD spread between cervids.
Prion transmission depends on the specific disease and host. Documented pathways include BSE-associated foodborne exposure, certain historical medical exposures, and direct or environmental transmission of CWD among susceptible cervids.
  • Ingestion– Prions present in infected tissues can enter the body with contaminated food. Variant Creutzfeldt-Jakob disease (vCJD) was transmitted through food containing bovine spongiform encephalopathy (BSE) prions.
  • Cannibalism– Kuru was transmitted among the Fore people by eating infected human tissues during ritual cannibalism.
  • Surgical instruments– Neurosurgical instruments contaminated with infected nervous tissue can transmit prions. Routine sterilization may not completely inactivate them.
  • Tissue grafts– Infected dura mater grafts and corneal grafts have transmitted Creutzfeldt-Jakob disease (CJD).
  • Pituitary hormones– Some cases of iatrogenic CJD occurred after treatment with human pituitary-derived growth hormone prepared from infected tissues.
  • Blood transfusion– Variant CJD has been transmitted through blood transfusion from infected donors. Such transmission has not been established for the common sporadic form of CJD.
  • Animal transmission– Prions can pass from an infected animal to another susceptible animal. Chronic wasting disease (CWD) spreads among deer, elk and other cervids.
  • Body secretions– Infected animals can release CWD prions in saliva, urine, faeces and other biological materials.
  • Environment– Prions released by infected animals can remain in soil and contaminate food or water. Susceptible animals may acquire CWD from these sources.
  • Cross-species transmission– Some prions can pass from one species to another. BSE prions passed from cattle to humans and caused vCJD.

Diagnosis of Prion Diseases

The important methods used for diagnosis of prion diseases are given below:

  • Neurological examination– The patient is examined for rapidly progressive dementia and neurological changes such as myoclonus, ataxia, visual disturbances and movement abnormalities. The course of the disease is also considered.
  • Magnetic resonance imaging (MRI)– MRI of the brain is used to detect characteristic signal changes in affected regions. Diffusion-weighted imaging (DWI) and FLAIR are commonly used in suspected CJD.
  • RT-QuIC test– Real-time quaking-induced conversion (RT-QuIC) is performed on cerebrospinal fluid (CSF) to detect prion seeding activity. A positive result provides strong evidence for prion disease, but the test is not positive in every case.
  • CSF biomarkers– The 14-3-3 protein and total tau can be measured in the CSF. These are markers of rapid neuronal injury and are not specific for prion disease.
  • Electroencephalography (EEG)– EEG may show periodic sharp wave complexes in some patients with sporadic CJD. This finding supports the diagnosis but is not present in all prion diseases.
  • PRNP genetic testing– The PRNP gene can be examined when a genetic prion disease is suspected. A pathogenic PRNP variant helps in the diagnosis of inherited prion disease.
  • Supportive tests– Clinical findings, MRI, EEG and CSF biomarkers are used together during the investigation of suspected prion disease. These findings can support the diagnosis but do not provide neuropathological confirmation.
  • Neuropathological examination– Definite confirmation requires examination of brain tissue by neuropathology and prion protein testing. The tissue may be obtained by biopsy or, more commonly, at autopsy.
  • Test sensitivity– The sensitivity and usefulness of RT-QuIC, MRI, EEG and other tests can differ among prion disease subtypes. A negative result from one test does not exclude every form of prion disease.

Treatment and Management of Prion Diseases

The treatment and management of prion diseases are given below:

  • There is no cure or specific treatment for prion diseases. The disease continues to progress after the symptoms develop.
  • Treatment is mainly given to reduce the symptoms and keep the patient comfortable.
  • Medicines may be used for anxiety, depression and behavioural changes.
  • Myoclonus, tremors and seizures may be controlled with medicines.
  • Pain-relieving medicines can be given when pain is present.
  • As movement becomes difficult, the patient may need help with walking, washing, dressing and other daily activities.
  • Difficulty in swallowing may develop during the later stages. Fluids and nutrition may be given through a feeding tube when required.
  • Nursing care is required when the patient becomes more dependent on others. Physiotherapy and other supportive care may also be needed.
  • Palliative or hospice care may be given during the advanced stages of the disease for the control of symptoms and patient care.
  • Family members and caregivers may also need practical and emotional support during the course of the disease.

Prevention of Prion Diseases

The following measures are used for the prevention of prion diseases:

  • There is no vaccine or preventive medicine available for prion diseases.
  • Food contaminated with prions should not be consumed. Control of bovine spongiform encephalopathy (BSE) in cattle helps to reduce the risk of variant Creutzfeldt-Jakob disease (vCJD).
  • Meat from animals that appear sick or test positive for chronic wasting disease (CWD) should not be eaten.
  • Hunters in CWD-affected areas may have deer or elk tested before eating the meat. The brain, spinal cord and other high-risk tissues should be handled carefully.
  • Medical instruments contaminated with high-risk tissues require special prion decontamination procedures. Routine cleaning and sterilization may not be sufficient.
  • Disposable instruments and materials contaminated with potentially infectious prion tissue may require destruction after use.
  • Tissue and organ donors are screened to reduce the possibility of transmitting prions through transplantation.
  • Healthcare workers should follow infection-control precautions while handling brain, spinal cord, eye tissue and other potentially infected materials.
  • Sporadic prion diseases cannot currently be prevented because they develop without a known external source of infection.
  • Genetic prion diseases cannot usually be prevented by avoiding exposure. Genetic testing and counselling may be considered in families with an inherited prion disease.

Prion Resistance and Inactivation

The resistance and inactivation of prions are given below:

  • Prions are resistant to many physical and chemical methods that normally destroy other infectious agents.
  • The abnormal prion protein has a stable folded structure and can form aggregates. It is also partly resistant to proteolytic enzymes.
  • Ordinary cooking temperatures do not reliably destroy prions. Prions may remain in cooked meat if the tissue was contaminated before cooking.
  • Routine disinfectants such as alcohol cannot be relied upon for prion inactivation.
  • Some standard sterilization procedures may reduce prion infectivity without removing it completely.
  • Strong chemical treatment with sodium hydroxide (NaOH) or sodium hypochlorite may be combined with steam sterilization (autoclaving) for prion decontamination.
  • These special treatments are used to reduce the infectivity of prions on contaminated instruments. Complete inactivation cannot be guaranteed in every condition.
  • Disposable materials contaminated with high-risk prion tissues may be destroyed by incineration.
  • Reusable instruments require special prion decontamination procedures and should be handled according to professional infection-control protocols.
  • Home cooking, ordinary cleaning and routine household disinfection should not be used for destroying prions.

Differences Between Prions, Viruses and Viroids

Prions, viruses and viroids are infectious agents, but they differ in their composition and genetic material. A prion is an infectious protein and is not a virus.

Molecular comparison showing a protein-only prion aggregate, a virus with a protein capsid and nucleic acid genome, and an unencapsidated circular RNA viroid.
Prions consist of infectious protein conformations, viruses package a DNA or RNA genome within a protein capsid, and viroids are small infectious RNA molecules without a protein coat.
CharacteristicsPrionsVirusesViroids
CompositionPrions are made only of abnormal infectious protein.Viruses contain nucleic acid surrounded by a protein coat (capsid). Some viruses also have an envelope.Viroids are made of small, circular single-stranded RNA.
Nucleic acidDNA and RNA are absent.Either DNA or RNA is present.Only RNA is present.
Genetic informationPrions do not contain a nucleic acid genome.The viral DNA or RNA carries the genetic information.The viroid RNA itself contains the genetic information, but it does not code for proteins.
Protein coatA separate protein coat is absent. The infectious agent itself is protein.A protein capsid surrounds the viral genome.A protein coat is absent.
PropagationPrions propagate by changing normal prion protein (PrP) into the abnormal form.Viruses replicate their nucleic acid and produce viral components inside the host cell.Viroid RNA is replicated by the enzymes of the host cell.
Host dependencePrions require the normal prion protein of the host for propagation.Viruses depend on living host cells for replication.Viroids depend on living plant cells for replication.
Cellular naturePrions are acellular infectious proteins.Viruses are acellular infectious particles.Viroids are acellular RNA agents.
HostsPrion diseases occur mainly in humans and other animals.Viruses infect animals, plants, fungi, bacteria and other organisms.Viroids mainly infect plants.
Protein synthesisPrions have no genetic material for protein synthesis.Viral genomes may code for viral proteins.Viroids do not code for proteins.
Examples of diseasesCreutzfeldt-Jakob disease (CJD), scrapie and bovine spongiform encephalopathy (BSE).Influenza, measles and acquired immunodeficiency syndrome (AIDS).Potato spindle tuber disease and citrus exocortis disease.

References

  • Acquatella-Tran Van Ba, I., Imberdis, T., & Perrier, V. (2013). From prion diseases to prion-like propagation mechanisms of neurodegenerative diseases. International Journal of Cell Biology, 2013, 975832. https://doi.org/10.1155/2013/975832
  • Acevedo-Morantes, C. Y., & Wille, H. (2014). The structure of human prions: From biology to structural models—Considerations and pitfalls. Viruses, 6(10), 3875–3892. https://doi.org/10.3390/v6103875
  • Appleby, B. S., Shetty, S., & Elkasaby, M. (2022). Genetic aspects of human prion diseases. Frontiers in Neurology, 13, 1003056. https://doi.org/10.3389/fneur.2022.1003056
  • Bellini, P., Ruggiero, F., Benedetti, A., Cereda, C. W., Gobbi, C., Bianco, G., & Bongiovanni, M. (2026). Human prion disease: Pathogenesis, diagnosis and public health. Viruses, 18(2), 216. https://doi.org/10.3390/v18020216
  • Benavente, R., Brydon, F., Bravo-Risi, F., Soto, P., Reed, J. H., Lockwood, M., Telling, G., Barria, M. A., & Morales, R. (2025). Detection of chronic wasting disease prions in raw, processed, and cooked elk meat, Texas, USA. Emerging Infectious Diseases, 31(2), 363–367. https://doi.org/10.3201/eid3102.240906
  • Burke, C. M., Walsh, D. J., Steele, A. D., Agrimi, U., Di Bari, M. A., Watts, J. C., & Supattapone, S. (2019). Full restoration of specific infectivity and strain properties from pure mammalian prion protein. PLOS Pathogens, 15(3), e1007662. https://doi.org/10.1371/journal.ppat.1007662
  • Cobb, N. J., & Surewicz, W. K. (2009). Prion diseases and their biochemical mechanisms. Biochemistry, 48(12), 2574–2585. https://doi.org/10.1021/bi900108v
  • Contiliani, D. F., de Araújo Ribeiro, Y., de Moraes, V. N., & Pereira, T. C. (2021). MicroRNAs in prion diseases—From molecular mechanisms to insights in translational medicine. Cells, 10(7), 1620. https://doi.org/10.3390/cells10071620
  • Fraser, P. E. (2014). Prions and prion-like proteins. Journal of Biological Chemistry, 289(29), 19839–19840. https://doi.org/10.1074/jbc.R114.583492
  • Hara, H., & Sakaguchi, S. (2021). Virus infection, genetic mutations, and prion infection in prion protein conversion. International Journal of Molecular Sciences, 22(22), 12439. https://doi.org/10.3390/ijms222212439
  • Krauss, S., & Vorberg, I. (2013). Prions ex vivo: What cell culture models tell us about infectious proteins. International Journal of Cell Biology, 2013, 704546. https://doi.org/10.1155/2013/704546
  • Le, N. T. T., Wu, B., & Harris, D. A. (2019). Prion neurotoxicity. Brain Pathology, 29(2), 263–277. https://doi.org/10.1111/bpa.12694
  • Linden, R., Cordeiro, Y., & Lima, L. M. T. R. (2012). Allosteric function and dysfunction of the prion protein. Cellular and Molecular Life Sciences, 69(7), 1105–1124. https://doi.org/10.1007/s00018-011-0847-7
  • Ma, J., & Wang, F. (2014). Prion disease and the ‘protein-only hypothesis’. Essays in Biochemistry, 56, 181–191. https://doi.org/10.1042/bse0560181
  • Manka, S. W., Wenborn, A., Collinge, J., & Wadsworth, J. D. F. (2023). Prion strains viewed through the lens of cryo-EM. Cell and Tissue Research, 392(1), 167–178. https://doi.org/10.1007/s00441-022-03676-z
  • Marrero-Winkens, C., Sankaran, C., & Schätzl, H. M. (2020). From seeds to fibrils and back: Fragmentation as an overlooked step in the propagation of prions and prion-like proteins. Biomolecules, 10(9), 1305. https://doi.org/10.3390/biom10091305
  • Mercer, R. C. C., & Harris, D. A. (2023). Mechanisms of prion-induced toxicity. Cell and Tissue Research, 392(1), 81–96. https://doi.org/10.1007/s00441-022-03683-0
  • Sanders, D. W., Kaufman, S. K., Holmes, B. B., & Diamond, M. I. (2016). Prions and protein assemblies that convey biological information in health and disease. Neuron, 89(3), 433–448. https://doi.org/10.1016/j.neuron.2016.01.026
  • Sang, J. C., Meisl, G., Thackray, A. M., Hong, L., Ponjavic, A., Knowles, T. P. J., Bujdoso, R., & Klenerman, D. (2018). Direct observation of murine prion protein replication in vitro. Journal of the American Chemical Society, 140(44), 14789–14798. https://doi.org/10.1021/jacs.8b08311
  • Schonberger, L. B., & Schonberger, R. B. (2012). Etymologia: Prion. Emerging Infectious Diseases, 18(6), 1030–1031. https://doi.org/10.3201/eid1806.120271
  • Sigurdson, C. J., Bartz, J. C., & Glatzel, M. (2019). Cellular and molecular mechanisms of prion disease. Annual Review of Pathology: Mechanisms of Disease, 14, 497–516. https://doi.org/10.1146/annurev-pathmechdis-012418-013109
  • Weissmann, C. (2012). Mutation and selection of prions. PLOS Pathogens, 8(3), e1002582. https://doi.org/10.1371/journal.ppat.1002582
  • Yakubu, U. M., Catumbela, C. S. G., Morales, R., & Morano, K. A. (2020). Understanding and exploiting interactions between cellular proteostasis pathways and infectious prion proteins for therapeutic benefit. Open Biology, 10(11), 200282. https://doi.org/10.1098/rsob.200282
  • Zerr, I., & Schmitz, M. (2021). Genetic prion disease. In GeneReviews®. University of Washington, Seattle. https://www.ncbi.nlm.nih.gov/books/NBK1229/

Comments

Leave a comment

Be the first to comment.